[AgNOR和PCNA在Barrett腺癌及其癌前病变中的表达及临床意义]
[Expression and clinical significance of the AgNOR and PCNA in Barrett's adenocarcinoma and its precancerous lesions].
作者信息
Li H, Yao S, Stuart R
机构信息
Department of Cardiothoracic Surgery, Naval General Hospital, Beijing.
出版信息
Zhonghua Zhong Liu Za Zhi. 1995 Jul;17(4):286-8.
In order to investigate the expression of AgNOR and PCNA in malignant Barrett's esophagus and benign Barrett's esophagus with or without dysplasia, 50 specimens and biopsies were examined using silver-staining and immunohistochemical methods. The results showed that the expression of AgNOR and PCNA in malignant Barrett's esophagus were higher than those in benign Barrett's esophagus with dysplasia, which were in turn higher than those in benign Barrett's esophagus without dysplasia. The difference between malignant group and other groups was significant. The results suggest that AgNOR and PCNA may be useful as an adjunct in screening patients with Barrett's esophagus for early malignant change, especially in high-grade dysplasia group.
为了研究AgNOR和PCNA在恶性巴雷特食管以及伴有或不伴有发育异常的良性巴雷特食管中的表达情况，采用银染法和免疫组化方法对50份标本及活检组织进行了检测。结果显示，恶性巴雷特食管中AgNOR和PCNA的表达高于伴有发育异常的良性巴雷特食管，而伴有发育异常的良性巴雷特食管中AgNOR和PCNA的表达又高于不伴有发育异常的良性巴雷特食管。恶性组与其他组之间的差异具有显著性。结果提示，AgNOR和PCNA可能有助于筛查巴雷特食管早期恶变患者，尤其是高级别发育异常组。
Zotero 插件